Comments from the Managing Director:
“Compared to the same period of last year, the first quarter of 2016 showed a
varied palette of sales successes in Canada and the USA, modest development in
Europe and declining sales in Asia and Rest of World. The highlights included
the successful launch of our new Easy Dropper, which will eventually replace the
glass bottles for our drops, and two meta-analyses that confirm the
effectiveness of BioGaia ProTectis in colic and the effectiveness of BioGaia
ProDentis in periodontitis. At the end of the period we distributed the shares
in IBT to our shareholders, and since that time IBT is an independent company
that is listed on Nasdaq First North,” says Axel Sjöblad, Managing Director of
BioGaia AB.
Period from 1 January – 31 March 2016
(Figures in brackets refer to the same period of last year. The comparative
figures in the balance sheet refer to 31 December 2015.)
· Net sales amounted to SEK 133.9 million (138.8), a decrease of SEK 4.9
million (4%).
· Net sales in the Paediatrics business area reached SEK 108.1 million
(115.3)¹, a decrease of SEK 7.2 million (6%).
· Net sales in the Adult Health business area amounted to SEK 21.1 million
(19.8), an increase of SEK 1.3 million (7%).
· Operating profit was SEK 46.1 million (52.6), a decrease of SEK 6.5 million
(12%). Excluding expenses in the former subsidiary IBT, operating profit was SEK
51.3 million (56.3).
· Profit after tax was SEK 33.6 million (43.2), a decrease of SEK 9.6 million
(22%).
· Earnings per share totalled SEK 1.95 (2.50).
· The period’s cash flow was SEK -4.8 million (37.8). Cash and cash
equivalents at 31 March 2016 amounted to SEK 221.5 million (226.9). BioGaia’s
former subsidiary IBT was distributed to BioGaia’s shareholders on 29 March
2016. Excluding IBT, the period’s cash flow was SEK 39.0 million.
Key events in the first quarter of 2016
· BioGaia distributed the shares in IBT on 29 March 2016 in accordance with
the resolution of the extraordinary general meeting.
· New meta-analysis confirms the effectiveness of BioGaia ProTectis in colic.
· Meta-analysis confirms the effectiveness of BioGaia ProDentis in periodontal
disease.
Key events after the end of the first quarter
· Agreement for the sale of BioGaia ProDentis in Hong Kong.
· BioGaia guarantees rights issue in IBT.
· Yet another meta-analysis confirms the effectiveness of BioGaia ProTectis in
colic.
1) A minor reallocation between the segments was made in the previous year’s
sales in order to achieve better comparability with the year’s figures.
Teleconference: You are welcome to take part in a teleconference on the interim
management statement that will be held today at 9:30 a.m. by Managing Director
Axel Sjöblad. To participate in the teleconference please see
www.biogaia.com/agenda. You can also follow the presentation at
http://financialhearings.nu/?160510/biogaia.
BioGaia has published this information in accordance with the Swedish Securities
Act. The information was issued for publication on 10 May 2016, 8.00 a.m.
This is a translation of the Swedish version of the interim report. When in
doubt, the Swedish wording shall prevail.
Latest press releases from BioGaia:
2016-05-02 Yet another meta-analysis confirms the effectiveness of BioGaia’s
probiotic in infantile colic
2016-04-27 BioGaia guarantees rights issue in IBT
2016-04-27 IBT’s results for the first quarter of 2016
For additional information contact:
Axel Sjöblad, Managing Director, BioGaia AB, telephone 46 8-555 293 00
or Margareta Hagman, Executive Vice President, BioGaia AB, telephone 46 8-555
293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
